The prognostic value of tumour-stroma ratio in triple-negative breast cancer

Moorman, A. M.; Vink, Robert; Heijmans, Harald J.; Palen, Job van der; Kouwenhoven, E.A.

doi:10.1016/j.ejso.2012.01.002

Cited by 113 publications

(113 citation statements)

References 40 publications

(30 reference statements)

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…In breast cancer, several immunohistochemistry studies have demonstrated that a high proportion of stroma (≥50 % of the tumour) is related to a poor outcome [18,25,73]. This result was also observed in colorectal cancer [46], and other authors demonstrated that tumours with low proportion of cancer cells are associated with poor overall and disease-free survival [70,113].…”

Section: Cancer-associated Fibroblasts As Target and Tool In Cancer Dmentioning

confidence: 57%

“…As Paulsson et al underlined, semiquantitative studies are observer-dependent and to have an idea about this inter-observer variation, a kappa value should be calculated. In those studies where a binary score is used, a good agreement between observers is generally obtained [18,25,46,73,82]. The main advantage of semi-quantitative analysis is its availability in every lab and its applicability in routine work.…”

Section: Cancer-associated Fibroblasts As Target and Tool In Cancer Dmentioning

confidence: 99%

See 1 more Smart Citation

Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics

et al. 2015

View full text Add to dashboard Cite

Cancer-associated fibroblasts (CAFs) are drivers of tumour progression and are considered as a target and a tool in cancer diagnostic and therapeutic applications. An increased abundance of CAFs or CAF signatures are recognized as a bad prognostic marker in several cancer types. Tumour-environment biomimetics strongly improve our understanding of the communication between CAFs, cancer cells and other host cells. Several experimental drugs targeting CAFs are in clinical trials for multiple tumour entities; alternatively, CAFs can be exploited as a tool to characterize the functionality of circulating tumour cells or to capture them as a tool to prevent metastasis. The continuous interaction between tissue engineers, biomaterial experts and cancer researchers creates the possibility to biomimic the tumour-environment and provides new opportunities in cancer diagnostics and management.

show abstract

Section: Cancer-associated Fibroblasts As Target and Tool In Cancer Dmentioning

confidence: 57%

Section: Cancer-associated Fibroblasts As Target and Tool In Cancer Dmentioning

confidence: 99%

Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Tumor stroma is an established prognostic marker for survival in women with breast cancer (9,26), largely due to stromal influence on tumor survival and metastasis. In the 2 mouse models, Cellax treatment depleted stroma and inhibited matrix deposition, decreased tumor IFP, increased perfusion, and significantly suppressed lung metastases.…”

Section: Discussionmentioning

confidence: 99%

Docetaxel Conjugate Nanoparticles That Target α-Smooth Muscle Actin–Expressing Stromal Cells Suppress Breast Cancer Metastasis

et al. 2013

View full text Add to dashboard Cite

Docetaxel-conjugate nanoparticles, known as Cellax, were synthesized by covalently conjugating docetaxel and polyethylene glycol to acetylated carboxymethylcellulose via ester linkages, yielding a polymeric conjugate that self-assembled into 120 nm particles suitable for intravenous administration. In 4T1 and MDA-MB-231 orthotopic breast tumor models, Cellax therapy reduced a-smooth muscle actin (a-SMA) content by 82% and 70%, respectively, whereas native docetaxel and nab-paclitaxel (albumin-paclitaxel nanoparticle, Abraxane) exerted no significant antistromal activity. In Cellax-treated mice, tumor perfusion was increased by approximately 70-fold (FITC-lectin binding), tumor vascular permeability was enhanced by more than 30% (dynamic contrast-enhanced magnetic resonance imaging), tumor matrix was decreased by 2.5-fold (immunohistochemistry), and tumor interstitial fluid pressure was suppressed by approximately 3-fold after Cellax therapy compared with the control, native docetaxel, and nab-paclitaxel groups. The antistromal effect of Cellax treatment corresponded to a significantly enhanced antimetastatic effect: lung nodules were reduced by 7-to 24-fold by Cellax treatment, whereas native docetaxel and nab-paclitaxel treatments were ineffective. Studies of the 4T1 tumor showed that more than 85% of the Cellax nanoparticles were delivered to the a-SMAþ stroma. Significant tumor stromal depletion occurred within 16 hours ($50% depletion) postinjection, and the a-SMAþ stroma population was almost undetectable ($3%) by 1 week. The 4T1 tumor epithelial cell population was not significantly reduced in the week after Cellax injection. These data suggest that Cellax targets tumor stroma and performs more efficaciously than docetaxel and nabpaclitaxel. Cancer Res; 73(15); 4862-71. Ó2013 AACR.

show abstract

“…In recent research, some new parameters have emerged that may have a prognostic role in colorectal cancer, one of them being the amount of stroma, which was fi rst demonstrated as a prognostic factor in breast and esophageal cancer [17][18][19][20][21][22] . Th e role of stroma proportion, or tumor cell proportion in the prognosis of colorectal cancer has been reported in four papers so far; they have demonstrated the proportion of stroma to be a signifi cant prognostic factor in colorectal cancer and the higher proportion of tumor stroma to be associated with better patient prognosis 24,25,28,29 .…”

Section: Discussionmentioning

confidence: 99%

“…It is believed that stroma induces tumorigenesis by various mechanisms such as remodeling of extracellular matrix, suppression of immune response and motility, as well as aggressiveness of cancer cells [15][16][17] . It has been evident that stroma has a prognostic value in esophageal cancer 18,19 and breast cancer 20 , especially triple negative breast cancer 21,22 . Using simple modifi ed methodology, we tried to determine the impact of stroma proportion on progression-free survival and overall survival.…”

Section: Introductionmentioning

confidence: 99%

High Tumor Stroma Proportion is a Worse Prognostic Factor in Colorectal Cancer

Flam¹

2017

acc

View full text Add to dashboard Cite

SUMMARY -High stroma proportion appears to be a very important prognostic factor in esophageal and breast cancer. Previous researches have shown that it might have a similar eff ect on colorectal cancer. Th e aim of this study was to determine whether tumor stroma proportion infl uenced patient survival. Th is retrospective study included 236 patients with colorectal cancer having undergone surgery in 2006 and 2007 at Osijek University Hospital Center. Location with the highest stroma proportion at the site of deepest tumor invasion was determined. Patients were divided into the groups with high stroma proportion (>50%) and low stroma proportion (≤50%). Stroma proportion showed a statistically signifi cant correlation with tumor stage. Kaplan-Meier survival curves yielded a statistically signifi cant diff erence in patient overall survival (Cox ph model p=0.016) and progressionfree survival (Cox ph model, p=0.0188) according to stroma proportion. Study results showed a statistically signifi cantly shorter overall survival and progression-free survival in patients with high stroma proportion.

show abstract

The prognostic value of tumour-stroma ratio in triple-negative breast cancer

Cited by 113 publications

References 40 publications

Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics

Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics

Docetaxel Conjugate Nanoparticles That Target α-Smooth Muscle Actin–Expressing Stromal Cells Suppress Breast Cancer Metastasis

High Tumor Stroma Proportion is a Worse Prognostic Factor in Colorectal Cancer

Contact Info

Product

Resources

About